# Evaluation of magnetic stimulation as a non-invasive technique in treating different causes of erectile dysfunction: a prospective cohort study

## TL;DR

This study shows that magnetic stimulation improves erectile dysfunction, especially for psychogenic cases, with significant improvements in sexual function scores.

## Contribution

The study evaluates the efficacy of Functional Magnetic Stimulator (FMS) in treating various causes of erectile dysfunction.

## Key findings

- FMS significantly improved IIEF-15 scores across all groups, with the highest improvement in psychogenic ED.
- Post-treatment scores for erectile function, orgasmic function, and overall satisfaction increased significantly.
- Psychogenic ED cases showed the most notable improvement after FMS sessions.

## Abstract

Elaboration of alternative therapeutic modality is needed, which should be safer, less costly and with no side effects. Functional Magnetic Stimulator (FMS) is a technique that was approved by the US Food and Drug Administration in 1998. We aimed to evaluate the efficacy of FMS in treating different causes of erectile dysfunction (ED).

The mean baseline 15 items of the international index of erectile function (IIEF-15) scores of groups A (arteriogenic ED), B (veno-occlusive ED) and C (psychogenic ED) were 12.8 ± 2.6, 16.2 ± 3.3 and 27.5 ± 3.7, respectively. The mean post sessions IIEF-15 scores of groups A, B and C were 23.4 ± 4.1, 31.5 ± 3.5, 49.2 ± 3.5, respectively. The mean baseline domains of erectile function (EF) scores of groups A, B and C were 3.8 ± 2, 5.8 ± 3.5 and 11.5 ± 3.1, respectively. The mean post sessions domains of EF scores of groups A, B and C were 10.6 ± 3.1, 15 ± 3.6 and 24.8 ± 2.9, respectively. The mean baseline domains of orgasmic function scores of groups A, B and C were 3.3 ± 0.9, 3.9 ± 0.5 and 4.8 ± 0.4, respectively. The mean post sessions domains of orgasmic function scores of groups A, B and C were 4.8 ± 0.8 5.9 ± 1.0 and 8.6 ± 0.5, respectively. The mean baseline domains of sexual desire scores of groups A, B and C were 2.6 ± 0.6, 3.1 ± 0.7 and 4.8 ± 0.7, respectively. The mean post sessions domains of sexual desire scores of groups A, B and C were 3.6 ± 0.5, 4.4 ± 0.7 and 6.6 ± 0.6, respectively. The mean baseline domains of intercourse satisfaction scores of groups A, B and C were 1.9 ± 0.5, 2.4 ± 0.6 and 4.1 ± 0.6, respectively. The mean post sessions domains of intercourse satisfaction scores of groups A, B and C were 2.6 ± 0.5, 3.6 ± 0.5 and 5.5 ± 0.6, respectively.

The baseline domains of overall satisfaction scores of groups A, B and C were 1.1 ± 0.3, 1.1 ± 0.3 and 2.4 ± 0.7, respectively. The mean post sessions domains of overall satisfaction scores of groups A, B and C were 2 ± 0.7, 2.7 ± 0.7 and 3.8 ± 0.7, respectively.

All patients showed significant improvement regarding domains of the IIEF-15 especially psychogenic cases following the sessions of FMS. Future studies should demonstrate the impact of these sessions on the response of poor responders to phosphodiesterase inhibitors and intracorporeal injections.